An Overview on Formulation and Development of Nanoparticulate Matrix Tablets for Beta Blockers
Nanotechnologies have a more attention in recants researches. It has more advantages over other technologies. New physical technologies and properties both at the same time in sample preparation and device fabrication evoke on account of the development. There is an exponential interest in the development of novel drug delivery systems with the help of nanoparticles. Solid lipid nanoparticles are aqueous colloidal dispersion of matrix. In this matrix is made up of biodegradable lipids. Various researchers are involved in this field because of its attention in the industry. There are many methods high shear homogenization, ultrasonication, Microemulsion, Solvent emulsification and diffusion method and solvent evaporation technique, double emulsion method, film ultrsound diffusion method etc. Solid Lipid Nanoparticles has the size ranges from 1 to 1000 nm particles can use for drug delivery system. Solid Lipid Nanoparticles with Beta blocker drugs gives us a big advantage over conventional drug delivery is to improve therapeutic efficacy and sustained drug release properties while overcoming the problems like poor solubility and low oral bioavailability of beta blocker drugs. Beta blocker drugs possess some drawbacks like low bioavailability, relatively short half-life, low permeability, and adverse side effects. For effective delivery of these beta blocker drugs, drug delivery systems are used to provide an alternative strategy to administer these agents with improved bioavailability and therapeutic effects of the beta blocker.
Keywords: Nanoparticles, Beta blocker, Homogenization, Microemulsion.
2. Ngwuluka NC, et al. Fabrication, Modeling and Characterization of Multi Cross linked Methacrylate copolymeric Nanoparticles for Oral Drug Delivery Int J Mol Sci.2011-12; 12(9):6194-6225.
3. Garud A, Singh D, Garud N. Solid Lipid Nanoparticles - Method, Characterization and Applications. International Current Pharmaceutical Journal 2012; 1(11): 384-393.
4. Bisht T, Rishiwer P, Kumar P. Review on Matrix Tablet. Indo Global Journal of Pharmaceutical Sciences 2016; 6(1): 38-42.
5. Mondal N. The Role of Matrix Tablet in Drug Delivery System. Int J App Pharm 2018; 10: 1-6.
6. Deepika B, Sameen S, Nazneen N, Madhavi A, Kandukoori NR, Dutt KR. Matrix drug delivery system- a review. Eur J Pharm Med Res 2018; 5(2), 150-154.
7. Kubova K, Pecek D, Hasserova K, Dolezel P, Pavelkova M, Vyslouzil J, et al. The influence of thermal treatment and type of insoluble polyacrylates on dissolution behavior of very soluble drug from Hypromellose matrix tablets evaluated by multivariate data analysis. Pharm Dev Technol 2017; 22(2):206-217.
8. Semjonov K, Kogermann K, Laidmäe I, Antikainen O, Strachan CJ, Ehlers H, et al. The formation and physical stability of two-phase solid dispersion systems of Indomethacin in super cooled molten mixtures with different matrix formers. Eur J Pharm 2017; 97:237.
9. Zalte HD, Saudagar RB. Review on Sustained Release Matrix Tablet. International Journal of Pharmacy and Biological Sciences 2013; 3:17-29.
10. Rao NG, Raj KR, Nayak SB. Review on Matrix Tablet as Sustained Release. International Journal of Pharmaceutical Research & Allied Sciences 2013; 2(3): 1-17
11. Saini N, George M, Joseph L. Matrix Tablets An Effective Way for Oral Controlled Release Drug Delivery Iran J Pharm Res Summer 2012; 8(3): 165-170
12. Jaimini M, Kothari A. Sustained Release Matrix Type Drug Delivery System: A Review Journal of Drug Delivery & Therapeutics 2012;2(6), 142-148
13. Karvekar M, Khan AB. A Brief Review on Sustained Release Matrix Type Drug Delivery System. Journal of Pharmaceutical Research 2017;16(3): 282-289
14. Koziolek M, Grimm M, Becker D, et al. Investigation of pH and temperature profiles in the GI tract of fasted human subjects using the Intellicap(®) system. J Pharm Sci 2015;104:2855–63
15. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9:799–809
16. Pridgen EM, Alexis F, Farokhzad OC. Polymeric nanoparticles technologies for oral drug delivery. Clin Gastroenterol Hepatol 2014; 12:1605–10
17. Neves AR, Queiroz JF, Lima SAC, et al. Cellular uptake and transcytosis of lipid-based nanoparticles across the intestinal barrier: relevance for oral drug delivery. J Colloid Interface Sci 2016; 463:258–65
18. Ghosh S, Roy T. Nanoparticulate drug-delivery systems: lymphatic uptake and its gastrointestinal applications. J Appl Pharm Sci 2014 4:123–30
19. Desai PP, Date AA, Patravale VB. Overcoming poor oral bioavailability using nanoparticles formulations – opportunities and limitations. Drug Discov Today Technol 2012; 9: e87–95
20. Niaz T, Shabbir S, Manzoor S, et al. Antihypertensive nano-ceuticales based on chitosan biopolymer: physico-chemical evaluation and release kinetics. Carbohyd Polym.2016; 142:268–74
21. Ekambaram P, Sathali AH. Solid lipid nanoparticles- a review. Chem. Commun 2016; 2(1), 80-102.
22. Sharma M, Sharma R, Jain DK. Nanotechnology Based Approaches for Enhancing Oral Bioavailability of Poorly Water Soluble Antihypertensive Drugs. Scientifica 2016; 2016:1-11.
23. Ramteke KH, Joshi SA, Dhole SN: Solid Lipid Nanoparticles- A Review. IOSR Journal of Pharmacy Nov-Dec. 2012; 2(6), PP.34-44.
24. Mohammed MA et al: An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery. Pharmaceutics: 2017; 9(4):53-78.
25. Betala S, Varma MM, Abbulu K: Formulation and evaluation of polymeric nanoparticles of an anti hypetensive drug for gastroretention. Journal of drug delivery and therapeutics: 2018; 8(6):82-86.
26. Ahad A, et al: Systemic delivery of β-blockers via Transdermal route for hypertension. Saudi Pharm J: 2015; 23(6):587–602.
27. Zimmer A, Kreuter J: Microspheres and nanoparticles used in ocular delivery systems. Advanced Drug Delivery. Adv Drug Deliv Rev 2016; 1995:61-73.
28. Venishetty V. K., Chede R., Komuravelli R., Adepu L., Sistla R., Diwan P. V. Design and evaluation of polymer coated Carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: a novel strategy to avoid intraduodenal administration. Colloids and Surfaces B: Biointerfaces. 2012; 95:1–9.
29. Sharma M, Sharma R, Jain DK. Nanotechnology Based Approaches for Enhancing Oral Bioavailability of Poorly Water-Soluble Antihypertensive Drugs. Scientifica (Cairo). 2016; 2016:8525679. doi:10.1155/2016/8525679
30. Thadkala K., Sailu C., Aukunuru J. Formulation, optimization and evaluation of oral nanosuspension tablets of Nebivolol hydrochloride for enhancement of dissoluton rate. Pharm Lett 2015; 7(3):71–84.
31. D'Emanuele A., Jevprasesphant R., Penny J., Attwood D. The use of a dendrimer-Propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Control Release 2004;95(3):447–453
32. Ahn BN., Kim S.-K., Shim C.-K. Preparation and evaluation of proliposomes containing Propranolol hydrochloride. J Microencapsul.1995; 12(4):363–375.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).